Virtual tour of Eurogentec’s In Vitro Diagnostic (IVD) GMP oligo facility
News Mar 25, 2010
The virtual tour allows decision makers in the IVD industry located in any part of the world to easily and quickly pre-audit the first-class clean room facility from their own computer without the need for expensive travel. Each of the classified clean rooms in the facility can be viewed in detail using interactive viewing features.
“The virtual tour provides decision makers evaluating Eurogentec as a potential supplier of custom-synthesized IVD oligonucleotides, an easy and innovative tool to pre-audit our GMP/QSR manufacturing facility and get a great impression of the extraordinary measures we have taken to minimize the risk of contamination,” says Dr. Peter Haima, Eurogentec’s Director for Diagnostic Services. “In June this year, we also plan to obtain ISO13485 certification of our GMP/QSR compliant clean room oligo production facility in North America. With this certification of its US site, Eurogentec’s strategic plan for having fully harmonized ISO13485-certified facilities in Europe, North America and Asia will be completed. Together, our harmonized global network of manufacturing facilities ensures our diagnostic clients an uninterrupted supply of cGMP-grade oligos.”
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE
Pap Test Fluids Used to Test for Endometrial & Ovarian CancersNews
Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center.